Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.39 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.35 |
| ▸ | NNMT | P40261 | 9/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29246916 | 0.86 | PIP4K2A (0.39) | SLC22A12PRMT5WDR77PIP4K2AFGFR1 | |
| SCHEMBL30372781 | 0.86 | PIP4K2A (0.39) | SLC22A12PRMT5WDR77PIP4K2AFGFR1 | |
| SCHEMBL16967987 | 0.84 | PIP4K2A (0.49) | SLC22A12PRMT5WDR77PIP4K2AFGFR1 | |
| SCHEMBL24753099 | 0.81 | PIP4K2A (0.44) | SLC22A12PRMT5WDR77PIP4K2A | |
| SCHEMBL1939828 | 0.81 | PIP4K2A (0.44) | SLC22A12PRMT5WDR77PIP4K2AFGFR1 | |
| SCHEMBL17877686 | 0.80 | PIP4K2A (0.44) | SLC22A12PRMT5WDR77PIP4K2AFGFR1 | |
| SCHEMBL12984832 | 0.80 | PRMT5 (0.42) | SLC22A12PRMT5WDR77PIP4K2ANNMT | |
| SCHEMBL16769947 | 0.79 | PRMT5 (0.44) | SLC22A12PRMT5WDR77PIP4K2ANNMT | |
| SCHEMBL23892218 | 0.79 | PRMT5 (0.47) | SLC22A12PRMT5WDR77PIP4K2ANNMT | |
| SCHEMBL1442966 | 0.78 | PIP4K2A (0.45) | SLC22A12PRMT5WDR77PIP4K2ANNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158697-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2017-06-08 | — | — | US | disclosed |
| US-20170158697-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2017-06-08 | — | — | US | disclosed |
| WO-2015077866-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158697-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | SLC22A12 4818/4885PRMT5 792/4885WDR77 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.